Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the formation of a Strategic & Scientific Advisory Board (SSAB) with three key appointments:Louis Kunkel, PhD, Beverly Davidson, PhD, and Jeffrey Chamberlain, PhD.
The SSAB will work closely with Sarepta’s management team to advance the Company’s platform technology in Duchenne muscular dystrophy (DMD), identify multiple new applications for Sarepta’s proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the Company’s pipeline.
“We are thrilled with the addition of these experts to our team of advisors,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. “The background and experience our SSAB members bring to Sarepta will be invaluable as we move our follow-on exon skipping therapy product candidates forward into later stage clinical development, but also as we work towards the goal of discovering complementary therapies to further improve the lives of patients with DMD and expanding our RNA technology for other genetic neuromuscular diseases. As we begin to build our SSAB, I am proud to have leaders the caliber of Drs. Kunkel, Davidson, and Chamberlain as founding members and look forward to working with them.”
The initial appointments to Sarepta’s Strategic & Scientific Advisory Board include:
Louis M. Kunkel, PhD, Past Chief of the Division of Genetics and currently a member of theDivision of Genetics and Genomics, Boston Children’s Hospital. Professor of Pediatrics and Genetics, Harvard Medical School; Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Worchester MA; HHMI Investigator, 1987-2010; and Member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Kunkel is an internationally recognized geneticist with decades of experience and scientific success in the understanding of the basis for muscular dystrophies. Dr. Kunkel is responsible for the identification of the gene and encoded protein, dystrophin. He has received numerous awards and honors for scientific leadership and achievement and currently serves as the committee chair for the Muscular Dystrophy Association (MDA), a committee he has been a member of for over 15 years.
Beverly Davidson, PhD, Director of the Raymond G Perelman Center for Cellular and Molecular Therapeutics and Arthur V. Meigs Chair in Pediatrics, Children’s Hospital of Philadelphia; Professor in the Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. Dr. Davidson’s research focuses on the pathogenesis and therapy of hereditary neurogenetic diseases and the role of noncoding RNAs in neural development. She is an internationally known expert in the study of inherited neurological diseases and the development of molecular therapies. Dr. Davidson has been named a fellow by the American Association for the Advancement of Science, received the NIH Mathilde Solowey Award, was elected to the Advisory Council for the American Society of Gene and Cell Therapy and NINDS council, and was past chair of the Medical Sciences Section for theAmerican Association for the Advancement of Science.
Jeffrey Chamberlain, PhD, Professor in the Departments of Neurology, Medicine, and Biochemistry; McCaw Endowed Chair in Muscular Dystrophy at the University of Washington; Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center ofSeattle. Dr. Chamberlain’s research is primarily focused on two major goals: to develop a better understanding of the molecular basis of the pathophysiology of muscle disorders, and to develop gene and cell therapies that will correct and treat the muscular dystrophies. Dr. Chamberlain is a close collaborator with a number of prominent institutions, including Children’s Hospital of Seattle, Fred Hutchinson Research Center, University of Rochester, andHarborview Medical Center. Dr. Chamberlain also serves on the advisory boards for CureDuchenne, Akashi Therapeutics, and Solid Ventures. (Original Source)
Shares of Sarepta Therapeutics closed yesterday at $33.52. SRPT has a 1-year high of $35 and a 1-year low of $11.33. The stock’s 50-day moving average is $31.74 and its 200-day moving average is $20.50.
On the ratings front, Sarepta Therapeutics has been the subject of a number of recent research reports. In a report issued on August 7, Cowen analyst Phil Nadeau reiterated a Hold rating on SRPT. Separately, on the same day, RBC’s Simos Simeonidis reiterated a Hold rating on the stock and has a price target of $35.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Phil Nadeau and Simos Simeonidis have a total average return of 29.9% and -17.7% respectively. Nadeau has a success rate of 70.9% and is ranked #76 out of 3731 analysts, while Simeonidis has a success rate of 23.5% and is ranked #3673.
Overall, 4 research analysts have assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $35.00 which is 4.4% above where the stock closed yesterday.
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.